

# CITATION REPORT

List of articles citing

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

DOI: 10.1111/liv.13746

Liver International, 2018, 38, 976-987.

**Source:** <https://exaly.com/paper-pdf/68927990/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
143	Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. <b>2018</b> , 151, 407-413		11
142	Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. <b>2018</b> , 2,		13
141	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <b>2019</b> , 52, 144-160		9
140	Mechanistic Studies of Idiosyncratic DILI: Clinical Implications. <b>2019</b> , 10, 837		38
139	Novel Delivery Systems for Checkpoint Inhibitors. <b>2019</b> , 6,		15
138	Hepatotoxicity of immune check point inhibitors: Approach and management. <b>2019</b> , 51, 1074-1078		19
137	Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. <b>2019</b> , 50, 800-808		26
136	Drug-induced liver injury. <b>2019</b> , 5, 58		148
135	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. <b>2019</b> , 35, 150926		5
134	Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. <b>2019</b> , 8,		13
133	Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. <b>2019</b> , 15, 231-244		45
132	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <b>2019</b> , 76, 368-380		26
131	Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury. <b>2019</b> , 170, 499-508		23
130	Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. <b>2019</b> , 19, 587-594		27
129	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <b>2019</b> , 16, 563-580		584
128	New treatment-induced adverse effects we need to learn as modern hepatologists. <b>2019</b> , 13, 391-394		
127	A Pictorial Essay of Immunotherapy: Complications that Internists Will See, Whether They Like it or Not. <b>2019</b> , 132, 808-815		1

126	Cell death in drug-induced liver injury. <b>2019</b> , 85, 31-74		25
125	EASL Clinical Practice Guidelines: Drug-induced liver injury. <b>2019</b> , 70, 1222-1261		327
124	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. <b>2019</b> , 10, 364-371		31
123	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <b>2019</b> , 14, 205-221		54
122	The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation. <b>2019</b> , 12, 122-129		32
121	Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. <b>2019</b> , 7, 47		16
120	Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury Issued by China Food and Drug Administration. <b>2019</b> , 9, 648-658		12
119	Liver damage related to immune checkpoint inhibitors. <b>2019</b> , 13, 248-252		25
118	Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors. <b>2020</b> , 96, 39-47		7
117	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. <i>Liver International</i> , <b>2020</b> , 40, 6-17	7.9	16
116	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <b>2020</b> , 16, 4439-4453		21
115	Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. <b>2020</b> , 115, 251-261		20
114	Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. <b>2020</b> , 35, 1042-1048		11
113	Quantitative Systems Toxicology Approaches to Understand and Predict Drug-Induced Liver Injury. <b>2020</b> , 24, 49-60		12
112	[Management of immune checkpoint inhibitors-induced liver toxicity in cancer]. <b>2020</b> , 107, 1056-1068		
111	Management of Immune Checkpoint Inhibitor Toxicities. <b>2020</b> , 12, 9139-9158		6
110	Approach to the patient with acute severe autoimmune hepatitis. <b>2020</b> , 2, 100149		8
109	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <b>2020</b> , 114, 102514		14

108	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <b>2021</b> , 106, 123-136		6
107	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
106	A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. <b>2020</b> , 126, 4485-4497		12
105	Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol. <b>2020</b> , 11, 2023-2030		3
104	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <b>2020</b> , 85, 106628		4
103	In silico prediction of drug-induced liver injury: Quo vadis?. <b>2020</b> , 13, 31-68		
102	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. <b>2020</b> , 72, 315-329		60
101	Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. <b>2020</b> , 63, 6436-6461		18
100	A review of cancer immunotherapy toxicity. <b>2020</b> , 70, 86-104		304
99	Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. <b>2020</b> , 130, 211-218		10
98	Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. <b>2020</b> , 10,		6
97	Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. <i>Liver International</i> , <b>2020</b> , 40, 1906-1916	7.9	20
96	The hepatotoxicity of Polygonum multiflorum: The emerging role of the immune-mediated liver injury. <b>2021</b> , 42, 27-35		14
95	Integrative microphysiological tissue systems of cancer metastasis to the liver. <b>2021</b> , 71, 157-169		4
94	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <b>2021</b> , 34, 823-833		1
93	Analysis of Risk Factors for Hepatotoxicity Induced by Immune Checkpoint Inhibitors. <b>2021</b> , 44, 16-21		5
92	Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. <b>2021</b> , 94, 20200663		1
91	The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events. <b>2021</b> , 34, 386-396		2

90	Onkologische Notfälle mit besonderer Berücksichtigung der Nebenwirkungen von Checkpoint-Inhibitoren. <b>2021</b> , 24, 963-972	0
89	Testing Possible Risk Factors for Idiosyncratic Drug-Induced Liver Injury Using an Amodiaquine Mouse Model and Co-treatment with 1-Methyl-d-Tryptophan or Acetaminophen. <b>2021</b> , 6, 4656-4662	2
88	Managing Immune checkpoint inhibitor induced hepatitis in a patient with concurrent hepatitis C. <b>2021</b> , 3, 10066	
87	Drug-Induced Liver Disease in Children. <b>2021</b> , 348-382	
86	Incidence, mortality, and risk factors of immunotherapy-associated hepatotoxicity: A nationwide hospitalization analysis. <b>2021</b> , 5, 28-32	
85	Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. <b>2021</b> , 44, 261-268	0
84	Imaging spectrum of adverse events of immune checkpoint inhibitors. <b>2021</b> , 76, 262-272	2
83	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. <b>2021</b> , 17, 411-424	11
82	Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. <b>2021</b> , 9, 730	4
81	Gastrointestinal disorders as immune-related adverse events.	
80	Radiological assessment of response and adverse events associated with novel systemic oncological therapies. <b>2021</b> , 76, 247-261	
79	Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. <b>2021</b> , 44, 261-268	0
78	Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer. <b>2021</b> , 5, 722-724	0
77	ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. <b>2021</b> , 116, 878-898	31
76	Post-immunotherapy imaging in lung cancer. <b>2021</b> ,	1
75	[Side effects of immune checkpoint inhibitor treatment of urological tumors]. <b>2021</b> , 60, 803-815	4
74	Managing toxicities associated with immune checkpoint inhibitors. <b>2021</b> , 34, 32-39	0
73	Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. <b>2021</b> , 173, 281-305	12

72	Immune checkpoint inhibitors: current status. <b>2021</b> ,		1
71	The presence of non-hepatic malignancy and its implication in pursuing liver transplantation. <b>2021</b> , 35, e14410		
70	Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). <b>2021</b> , 23, 99		
69	Immune checkpoint inhibitor-related hepatotoxicity: A review. <b>2021</b> , 27, 5376-5391		10
68	Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 711217	8.4	1
67	Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. <b>2021</b> ,		2
66	Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report. <b>2021</b> , 11, 664809		2
65	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. <b>2021</b> , 139-173		
64	Non-Rheumatic Immune-Related Adverse Events. <b>2021</b> , 191-253		
63	Checkpoint Inhibitors and Hepatotoxicity. <b>2021</b> , 9,		4
62	Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists. <b>2020</b> , 45, 2624-2636		1
61	Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. <b>2020</b> , 151, 102979		3
60	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <b>2020</b> , 20, 1047-1059		3
59	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. <b>2020</b> , 10, 143		8
58	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. <b>2020</b> , 8, 9-22		4
57	Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. <b>2019</b> , 25, 6579-6606		13
56	Management of Immunotherapy-Related Toxicities, Version 1.2019. <b>2019</b> , 17, 255-289		246
55	The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. <b>2021</b> , 11, 4628-4634		

54	Mechanisms of immune checkpoint inhibitor-mediated liver injury.. <b>2021</b> , 11, 3727-3739		5
53	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma.		2
52	A Case of Malignant Melanoma with Severe Liver Dysfunction Induced by Nivolumab. <b>2019</b> , 34, 192-197		
51	Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. <b>2019</b> , 10, 37-46		5
50	Immune-related adverse events associated with immune check-point inhibitors. <b>2019</b> , 33, 20-24		1
49	Side effects and management in immunotherapy based on immune checkpoint inhibitors. <b>2020</b> , 28, 755-764		0
48	Biochemical mechanisms of drug toxicity. <b>2022</b> , 267-302		
47	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. <b>2021</b> , 12, 747416		
46	Management of hepatotoxicity of chemotherapy and targeted agents. <b>2021</b> , 11, 3461-3474		1
45	Gastrointestinal adverse events of immunotherapy. <b>2021</b> , 3,		
44	Immune Checkpoint Inhibitor-Induced Gastrointestinal Toxicity: The Opinion of a Gastroenterologist.. <i>Cureus</i> , <b>2021</b> , 13, e19945	1.2	0
43	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
42	Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
41	Plasmapheresis for Pembrolizumab-Induced Hepatitis in a Patient with Squamous Cell Carcinoma and Prior Orthotopic Liver Transplantation.. <i>Case Reports in Hepatology</i> , <b>2022</b> , 2022, 5908411	0.9	0
40	Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 809063	5.7	
39	Immunotherapy-Induced Acute Hepatitis in the Elderly: The Case of a Patient with Urothelial Carcinoma and a Review of the Literature. <i>Forum of Clinical Oncology</i> , <b>2022</b> ,	0.3	0
38	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 804597	8.4	4
37	Incidence and risk factors of drug-induced liver injury.. <i>Liver International</i> , <b>2022</b> ,	7.9	0

36	Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	2
35	Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 148, 647	4.9	2
34	Quantitative Systems Toxicology and Drug Development: The DILIsym Experience.. <i>Methods in Molecular Biology</i> , <b>2022</b> , 2486, 181-196	1.4	0
33	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
32	Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States.. <i>Cureus</i> , <b>2022</b> , 14, e24053	1.2	0
31	Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. <i>Healthcare (Switzerland)</i> , <b>2022</b> , 10, 763	3.4	1
30	[Oncological emergencies with special consideration of the side effects of checkpoint inhibitors].. <i>Medizinische Klinik - Intensivmedizin Und Notfallmedizin</i> , <b>2022</b> , 1	3.2	
29	Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.. <i>Cancer Reports</i> , <b>2022</b> , e16245	1.5	0
28	Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort. <i>Liver International</i> ,	7.9	2
27	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. <i>Clinical Drug Investigation</i> ,	3.2	
26	Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. <i>World Journal of Hepatology</i> , <b>2022</b> , 14, 1269-1276	3.4	0
25	A new framework for advancing in Drug-Induced Liver Injury research. The Prospective European DILI Registry. <i>Liver International</i> ,	7.9	1
24	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists' Perspectives. <b>2022</b> , 14, 244-253		
23	Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. <b>2022</b> , 14, 1762		0
22	Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore).		
21	Drug induced liver injury by immunotherapy. <b>2022</b> ,		0
20	Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.		0
19	Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma. <b>2022</b> , 14, 4369		0



18 Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. ○

17 Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. **2022**, 10, e005635 ○

16 Gastrointestinal and Hepatic Complications in Cancer Patients. 1-18 ○

15 Imaging of Immune Checkpoint Inhibitor Immunotherapy for NonSmall Cell Lung Cancer. **2022**, 42, 1956-1974 2

14 A Review of Immune Checkpoint Blockade for the General Surgeon. **2023**, 281, 289-298 ○

13 PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study. 13, ○

12 Baseline risk factors associated with immune related adverse events and atezolizumab. ○

11 Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. **2022**, 117, 1917-1932 ○

10 Protective effect of resveratrol against pembrolizumab-induced hepatotoxicity and neurotoxicity in male rats. ○

9 Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma with EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy. 12, ○

8 Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. ○

7 Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Publish Ahead of Print, ○

6 Cholestasis in a cancer patient: think about the unicorn. **2022**, 85, 652-653 ○

5 Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. 1

4 Drug-induced liver injury: An overview and update. **2023**, ○

3 Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. **2023**, 15, 117-126 1

2 Baseline risk factors associated with immune related adverse events and atezolizumab. 13, ○

1 Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014-2021. **2023**, 18, e0281983 ○

